Profile data is unavailable for this security.
About the company
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd a China-based company principally engaged in the independent research and development and customized research and development and production of peptide drugs and small molecule drugs. The Company's main business includes customized product business and independently selected product business. Its customized product business includes CDMO (Contract Development and Manufacturing Organization) business, technical service CRO (Contract Research Organization) and transfer business. Its independently selected product business focuses on small molecule chemical drugs and conducts drug research and development in the key treatment areas of diabetes, cardiovascular diseases, tumors and other diseases. The Company mainly operates its businesses in the domestic market and overseas markets.
- Revenue in CNY (TTM)1.18bn
- Net income in CNY208.25m
- Incorporated2009
- Employees1.55k
- LocationJiangsu Sinopep Allsino Biopharmaceutical Co Ltd#28 Linpu RoadEconomic Technology Development ZoneLIANYUNGANG 311121ChinaCHN
- Phone+86 57 186297893
- Fax+86 57 186298631
- Websitehttp://www.sinopep.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangxi Tianxin Pharmaceutical Co Ltd | 1.80bn | 514.80m | 11.36bn | 2.47k | 22.06 | 2.61 | -- | 6.31 | 1.18 | 1.18 | 4.11 | 9.95 | 0.36 | 2.68 | 6.66 | 727,792.60 | 10.31 | -- | 11.11 | -- | 39.78 | -- | 28.63 | -- | 5.51 | -- | 0.0551 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.73bn | 511.96m | 11.64bn | 2.55k | 22.69 | 1.48 | -- | 4.27 | 0.5447 | 0.5447 | 2.90 | 8.35 | 0.2186 | 1.58 | 0.8134 | 1,071,832.00 | 4.06 | 3.48 | 5.61 | 4.78 | 46.09 | 38.93 | 18.56 | 10.08 | 2.35 | -- | 0.2862 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| Mayinglong Pharmaceutical Group Co Ltd | 3.26bn | 453.31m | 12.36bn | 2.88k | 27.26 | 3.16 | -- | 3.79 | 1.05 | 1.05 | 7.56 | 9.08 | 0.6482 | 5.87 | 11.13 | 1,130,851.00 | 9.26 | 10.82 | 11.03 | 13.47 | 42.87 | 41.18 | 14.29 | 14.08 | 5.18 | -- | 0.0729 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.18bn | 208.25m | 12.47bn | 1.55k | 59.89 | 5.54 | -- | 10.56 | 0.9769 | 0.9769 | 5.54 | 10.55 | 0.3743 | 1.21 | 4.71 | 764,598.40 | 6.69 | 5.86 | 9.15 | 7.59 | 63.15 | 55.41 | 17.87 | 17.20 | 1.08 | 33.77 | 0.3356 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 191.35m | -1.02bn | 13.35bn | 1.49k | -- | 5.55 | -- | 69.75 | -2.55 | -2.55 | 0.4789 | 6.02 | 0.0412 | 0.0472 | 16.79 | 128,337.60 | -22.02 | -37.61 | -26.37 | -45.95 | 96.84 | 81.54 | -534.78 | -2,112.26 | 1.96 | -- | 0.442 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 5.25bn | 989.32m | 13.42bn | 4.88k | 13.53 | 1.54 | -- | 2.56 | 1.10 | 1.10 | 5.84 | 9.69 | 0.4523 | 1.87 | 4.36 | 1,076,055.00 | 8.52 | 10.10 | 11.07 | 13.69 | 35.80 | 34.64 | 18.83 | 16.26 | 2.07 | -- | 0.1816 | 40.79 | 1.44 | 24.29 | 12.20 | 45.74 | 32.14 | 20.11 |
| Changchun BCHT Biotechnology Co | 1.92bn | 543.19m | 13.49bn | 1.24k | 24.78 | 3.30 | -- | 7.04 | 1.32 | 1.32 | 4.64 | 9.88 | 0.4116 | 0.8459 | 1.55 | 1,543,550.00 | 11.67 | 9.95 | 14.14 | 12.81 | 89.90 | 86.63 | 28.36 | 24.03 | 2.03 | -- | 0.0158 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.43bn | 523.43m | 13.62bn | 8.41k | 26.23 | 1.91 | -- | 2.12 | 0.202 | 0.202 | 2.49 | 2.78 | 0.5568 | 2.39 | 4.60 | 764,058.90 | 5.02 | 6.77 | 7.25 | 10.50 | 54.36 | 63.24 | 9.02 | 11.10 | 1.53 | 40.71 | 0.1459 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
Data as of Jun 07 2024. Currency figures normalised to Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
20.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 12.54m | 8.77% |
| China Fund Management Co., Ltd.as of 31 Dec 2023 | 3.61m | 2.52% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 3.41m | 2.39% |
| HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 3.09m | 2.16% |
| Great Wall Fund Management Co., Ltd.as of 31 Dec 2023 | 2.42m | 1.69% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 1.22m | 0.86% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 807.44k | 0.56% |
| China Post & Capital Fund Management Co., Ltd.as of 31 Dec 2023 | 680.00k | 0.48% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 553.76k | 0.39% |
| AXA-SPDB Investment Managers Co., Ltd.as of 31 Dec 2023 | 442.36k | 0.31% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
